Study of how a new anemia drug, daprodustat, compares to darbepoetin alfa.

What we are studying

The purpose of this study is to test how effective daprodustat (an investigational medicine which has not yet been approved by regulatory agencies) is compared with epoetin alfa or darbepoetin alfa ([which has been approved /which is not approved]) (called EPO from here on) to treat your anemia and to see how safely this can be done over a long period of time.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 99

Eligibility Criteria

  • Use of approved epogen stimulating agent (ESA)
  • On dialysis
  • Compliance with placebo period
  • Able to give informed consent.

What is involved

  • 1 kidney ultrasound
  • 26 lab draws
  • 28 visits

Compensation

$60 - $180 per visit depending on procedures

Contact Information

Study Coordinator
Kendrah Kidd
Email
kkidd@wakehealth.edu
Phone
336-716-7162
Principal Investigator
Anthony J. Bleyer, MD, MS

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.